uploads///Article

How Do Credit Rating Agencies Rank Novartis?

By

Jun. 22 2016, Updated 2:17 p.m. ET

Updated June 22, 2016.

Article continues below advertisement

Understanding leverage

Novartis (NVS), a Swiss-based multinational pharmaceutical giant, has operations worldwide. The company uses both equity and debt for its working capital requirements as well as investments in business.

Net-debt-to-earnings

Net debt-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) is a measure of leverage. It’s calculated by subtracting a company’s cash or cash equivalents from its interest-bearing liabilities, and dividing that by its EBITDA. If a company has more cash than debt, the ratio can be negative.

The above chart compares Novartis’s net-debt-to-EBITDA with that of other companies including Pfizer (PFE), Bristol-Myers Squibb (BMY), Eli Lily (LLY), and Merck (MRK). Bristol-Myers Squibb’s cash and marketable securities are greater than its total debt, which gives it a negative net-debt-to-EBITDA.

Article continues below advertisement

Total debt to equity

Total debt to equity is a measure of financial leverage, calculated as total debt liabilities divided by shareholder equity. Novartis’s total-debt-to-equity ratio is 39.1%. Peers Pfizer, Bristol-Myers Squibb, Eli Lily, and Merck have ratios of 62.2%, 46.4%, 54.1%, and 58.7%, respectively.

Credit ratings and leverage

Leverage ratios determine a company’s ability to repay its debt. These also directly affect the company’s credit ratings. A higher net-debt-to-EBITDA ratio suggests that the company may not be able to service its debt in an appropriate manner, which lowers its credit rating. Similarly, the company with a lower net-debt-to-EBITDA ratio can take on more debt whenever needed and gets a higher credit rating.

Credit rating agencies Fitch, S&P, and Moody’s have respectively rated Novartis AA, AA-, and Aa3 for long-term debt. Lenders consider this a stable rating.

Details of debt

Novartis’s total gross financial debt rose by $2 billion to $21.9 billion in 2015. The company issued three Swiss-franc-denominated bonds in the first half of 2015 and two dollar-denominated bonds in the fourth quarter of 2015. The total amount raised through bonds was $4.5 billion during 2015, which was partially offset by the maturity of dollar-denominated bonds worth $2 billion and Swiss-franc-denominated bonds worth $0.9 billion.

Novartis forms about 5.5% of the VanEck Vectors Pharmaceutical ETF (PPH).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.